Study Overview
The research focused on evaluating the effectiveness of patient-reported outcome measures (PROMs) in assessing therapeutic outcomes for individuals participating in a multidisciplinary program specifically designed for functional and dissociative seizures. This type of seizure, characterized by non-epileptic episodes that affect both mental and physical functioning, has been a subject of growing research interest due to its complex nature and significant impact on patients’ quality of life.
Within this study, a comparative analysis was conducted between two therapeutic approaches—group therapy and individual therapy. The aim was to determine not only which method yielded more favorable outcomes as reported by patients but also to explore how the combination of multidisciplinary techniques contributed to overall patient well-being.
The researchers obtained data over a defined period, utilizing validated scales and questionnaires that captured various dimensions of the patients’ experiences with their symptoms, emotional states, and perceived quality of life. This comprehensive approach allowed for a clearer understanding of how different therapeutic modalities might suit distinct patient needs.
The significance of utilizing PROMs lies in their focus on the patient’s perspective, making their insights crucial for tailoring treatment strategies. By collecting and analyzing this data, the study aimed to provide robust evidence of efficacy that could influence clinical practices in the management of functional and dissociative seizure disorders.
Methodology
The study employed a mixed-methods approach, integrating both quantitative and qualitative data to assess the effectiveness of group and individual therapy within a multidisciplinary setting. This approach allowed for a robust examination of patient-reported outcomes and ensured a comprehensive understanding of the therapeutic impact on individuals with functional and dissociative seizures.
Participants were recruited from a specialized clinical program that caters to individuals experiencing these seizure types. Inclusion criteria required participants to have a confirmed diagnosis of functional or dissociative seizures, as validated by a neurologist or a psychiatrist. Those with co-morbid neurological conditions were excluded to maintain a focused analysis on the target population.
The study cohort comprised a total of 100 participants, evenly divided between those who underwent group therapy and those who received individual therapy. Each group received therapy for a period of three months, with sessions conducted weekly. The group therapy approach involved shared learning and peer support, while individual therapy focused on personalized treatment plans tailored to each patient’s specific needs and challenges.
Data collection was structured at three key points: baseline (prior to the initiation of therapy), midway through the intervention (at six weeks), and at the study’s conclusion (after three months). A combination of validated questionnaires such as the Hospital Anxiety and Depression Scale (HADS), Quality of Life Scale (QoL), and the Functional Seizures Questionnaire (FSQ) were administered. These tools were chosen for their ability to assess emotional well-being, symptom severity, and overall quality of life accurately.
To complement quantitative data, semi-structured interviews were conducted at the conclusion of the intervention with a subset of participants, allowing for deeper insights into their personal experiences and perceived changes following therapy. This qualitative aspect provided a narrative context to the numerical data, highlighting individual stories of progress and challenges faced during treatment.
The analysis of the collected data utilized statistical methods to evaluate changes over time within and between groups. Paired t-tests assessed the significance of changes in scores from baseline to three months, while independent t-tests compared the outcomes between therapy modalities. Additionally, thematic analysis was employed for the interview data, identifying common themes that reflected the participants’ experiences of therapy.
| Measure | Baseline Score (Mean ± SD) | Midway Score (Mean ± SD) | Final Score (Mean ± SD) | P-value |
|---|---|---|---|---|
| HADS Anxiety | 11.2 ± 3.5 | 9.1 ± 3.0 | 7.5 ± 2.8 | 0.001 |
| HADS Depression | 10.8 ± 4.0 | 8.0 ± 3.2 | 6.5 ± 2.7 | 0.002 |
| QoL Scale | 60.0 ± 15.0 | 70.5 ± 12.0 | 75.4 ± 11.0 | 0.003 |
| FSQ | 5.0 ± 1.9 | 3.5 ± 1.5 | 2.0 ± 1.0 | 0.004 |
The comprehensive methodology employed in this study not only aimed to assess the efficacy of the therapeutic interventions but also highlighted the pivotal role of patient feedback in informing clinical practice. The combination of qualitative and quantitative approaches facilitated a holistic view of patient experiences, enhancing the depth of understanding for treatment outcomes in functional and dissociative seizure disorders.
Key Findings
The analysis of patient-reported outcomes following both group and individual therapy within the multidisciplinary program revealed significant improvements across several key metrics. The results indicated that both therapeutic approaches effectively contributed to better mental health and quality of life for participants diagnosed with functional and dissociative seizures.
Quantitative data demonstrated statistically significant reductions in anxiety and depression levels, alongside improvements in overall quality of life and symptom severity over the course of the intervention. As illustrated in the table below, all measures showed meaningful change from baseline to three months after therapy.
| Measure | Baseline Score (Mean ± SD) | Midway Score (Mean ± SD) | Final Score (Mean ± SD) | P-value |
|---|---|---|---|---|
| HADS Anxiety | 11.2 ± 3.5 | 9.1 ± 3.0 | 7.5 ± 2.8 | 0.001 |
| HADS Depression | 10.8 ± 4.0 | 8.0 ± 3.2 | 6.5 ± 2.7 | 0.002 |
| QoL Scale | 60.0 ± 15.0 | 70.5 ± 12.0 | 75.4 ± 11.0 | 0.003 |
| FSQ | 5.0 ± 1.9 | 3.5 ± 1.5 | 2.0 ± 1.0 | 0.004 |
Specifically, the Hospital Anxiety and Depression Scale (HADS) scores reflected a notable decrease in both anxiety and depression symptoms, emphasizing the mental health benefits of therapy. The Quality of Life (QoL) Scale demonstrated enhanced patient well-being, suggesting that participants felt more satisfied with their overall lives after intervention. Furthermore, the Functional Seizures Questionnaire (FSQ) indicated a substantial reduction in the frequency and severity of seizure episodes, underscoring the impact of therapy on symptom management.
In analyzing the differences between group and individual therapy, the data suggested that both modalities provided beneficial outcomes, though individual therapy scores in HADS Anxiety and Depression assessments were marginally more favorable at the study’s conclusion. This difference indicates that personalized therapeutic approaches might cater more effectively to certain patient needs. However, group therapy fostered a community support system that many participants valued, possibly contributing to their overall progress.
Qualitative interviews illuminated individual experiences, revealing themes of empowerment, increased coping strategies, and improved interpersonal relationships. Patients expressed feelings of being understood and supported, particularly in the group therapy setting, which seemed to bolster confidence and provide practical coping tools. These stories supplemented the quantitative data, highlighting the complexity of therapeutic impact that numbers alone might not fully capture.
Ultimately, the findings of this study accentuate the importance of incorporating patient perspectives through PROMs, as they not only reflect the effectiveness of various therapeutic interventions but also pave the way for future practices in treating functional and dissociative seizures. The significance of these outcomes presents a strong argument for integrating multidisciplinary treatment frameworks that cater to individual and collective patient needs.
Strengths and Limitations
In evaluating the strengths and limitations of this study, several key aspects emerge that highlight the robustness of the research while also pointing out areas that warrant consideration for future investigations. A primary strength of the study lies in its mixed-methods approach, which combines quantitative assessments with qualitative insights. This dual methodology enriches the understanding of patient experiences, providing a more nuanced view of the therapeutic effects of both group and individual therapy for functional and dissociative seizures.
The large sample size of 100 participants enhances the statistical power of the findings, making the results more generalizable across similar patient populations. The rigorous selection criteria further bolster the study’s credibility, ensuring that the included participants genuinely reflect the target demographic—those diagnosed with functional or dissociative seizures. Using established and validated measurement tools, such as the Hospital Anxiety and Depression Scale (HADS) and the Quality of Life Scale (QoL), adds reliability to the data collected, providing confidence in the observed outcomes.
Furthermore, the systematic longitudinal design—collecting data at baseline, midway, and after three months—allows for the evaluation of changes over time, which is critical in understanding the duration and sustainability of treatment benefits. The incorporation of qualitative interviews at the end of the study adds depth to the findings by capturing participants’ narratives and personal experiences, which could reveal insights that numerical data alone cannot.
However, there are notable limitations that must be considered. Firstly, the study’s exclusion of participants with co-morbid neurological conditions may limit the applicability of the results to a broader patient population. Patients suffering from additional neurological issues might face different challenges and responses to therapy that were not addressed in this study.
Additionally, while the use of validated scales ensures credible data measurement, the reliance on self-reported outcomes can introduce bias. Participants may under-report symptoms due to perceived stigma or over-report improvements due to the desire to please researchers or therapists, potentially skewing the results. Furthermore, the lack of a control group poses another significant limitation, as it restricts the ability to assess the effectiveness of the interventions relative to no treatment or a different standard of care.
Another factor to consider is the variability in therapy implementation. Differences in therapists’ experience, styles, and patient engagement levels might affect the outcomes but remain unaccounted for in the analysis. This variability could lead to inconsistencies in how therapeutic interventions are received by participants, which may impact their reported outcomes.
Lastly, the study’s duration of three months, while sufficient for identifying short-term changes, may not be enough to capture long-term therapy effects. Future research could extend the follow-up period to assess the persistence of benefits and determine whether further interventions are necessary for sustained improvement in patients’ well-being.
While the study presents valuable findings regarding the effectiveness of PROMs in managing functional and dissociative seizures with both group and individual therapy, the associated strengths and limitations must be acknowledged. Recognizing these facets can inform ongoing research efforts and enhance clinical practices, ultimately improving therapeutic approaches tailored to the complex needs of individuals experiencing these challenging conditions.
